Visual Medtech Secures RMB 100 Million Series A Funding Led by China Merchants Capital to Advance Digital Surgery Platform

VCBeat (WeChat: vcbeat) learned at the earliest opportunity that,Recently, Visual MedTech Co., Ltd. (hereinafter referred to as “Visual MedTech”), a digital surgery platform company centered on its full-process intelligent surgical robot system, announced the completion of its RMB 100 million Series A financing round. The round was led by China Merchants Capital Co., Ltd., with co-investment from Beijing Lang Ma Feng VC LTD., and follow-on investments from funds affiliated with the Jiangsu Provincial Sino-Israel Industrial Technology Research Institute. Existing shareholders, including Legend Capital, Yuanju Capital, and Zhuoxiang Technology, continued to increase their stakes. The proceeds from this financing will be used for product clinical trials and market promotion. WinX Capital served as the exclusive financial advisor for this financing round.

Visual MedTech, established in 2016, is a pioneer, explorer, and practitioner of comprehensive digital surgery solutions in China. The company is dedicated to assisting clinicians in performing precise, minimally invasive digital surgeries, thereby benefiting a vast number of patients. It has integrated a core team that was among the first in China to explore the integration of medicine and engineering, as well as the independent research, development, industrialization, and commercialization of surgical robots. Since its inception, leveraging over two decades of professional R&D expertise and industry application experience accumulated by its in-house team, Visual MedTech has aligned itself with the emerging global trends in next-generation digital surgery. The company has fully developed an end-to-end intelligent surgical robot system synchronized with international standards, comprising series products such as remote information interaction, AI-based surgical planning, navigated surgical robots, digital consumables, and supporting intelligent tools. It is gradually forming comprehensive digital surgery solutions covering multiple disciplines, including orthopedics, neurosurgery, and urology, comprehensively benchmarking against the forward-looking layouts of international giants like Medtronic and Johnson & Johnson in the field of intelligent surgery.

Recently, the orthopedic surgical robot independently developed by Visual MedTech has entered the clinical registration phase. This system has achieved multiple technological breakthroughs, including intelligent preoperative surgical planning, precise pre-selection of internal implants, accurate intraoperative navigation-guided manipulation, “zero-fluoroscopy” X-ray guidance, and rapid 2D/3D image registration. These innovations set an international precedent and have yielded satisfactory clinical outcomes in dozens of preliminary clinical trial surgeries. In addition, several other products from the company have entered the type-testing phase, with medical device registration certificates expected to be obtained within the next one to two years, paving the way for their gradual market entry. Furthermore, Visual MedTech has engaged in deep collaboration with Huawei. Together, they have developed an intelligent remote interaction product called “Yuepianbao” (Film Reading Assistant), which is accelerating its clinical deployment. This solution effectively resolves previous challenges in image interaction during remote consultations, offering a novel experience for case discussions, teaching rounds, and doctor-patient communication. It has been highly acclaimed by clinicians and lays a solid market foundation for the subsequent launch of a series of products comprising comprehensive end-to-end digital surgical solutions.

Dr. Lu Tong, Chairman of Visual MedTechStatement: We extend our sincere gratitude to both new and existing shareholders for their recognition of the company. The future belongs to the era of digital medicine, where traditional experience-based medicine will inevitably be replaced by more comprehensive and precise digital diagnostic and therapeutic technologies. Guided by this major trend, we have committed to developing end-to-end, cross-generational holistic solutions for digital surgery, driving surgical procedures toward greater functionality, modularity, integration, and platform-based development. This evolution is fostering a new landscape of intelligent surgical ecosystems and ushering in a new epoch in the field of medicine. To date, supported by our "medical-engineering collaboration" team, we have developed a series of products that align with the development trends of digital surgery and meet real-world clinical needs. These products offer versatility and scalability across multiple specialties. We hope that Visual MedTech can assist more clinical experts in providing patients with more efficient solutions.

Zhu Zhengwei, Senior Managing Director of China Merchants CapitalStatement: We recognize that the industrial transformation from traditional surgery to digital surgery presents a significant investment opportunity. As a pioneer in the field of digital surgery and surgical robotics in China, Visual MedTech boasts strong technical capabilities. Its long-standing model of integrating medical practice with engineering R&D has yielded systematic achievements, laying a solid foundation for sustained long-term development. The founding team, represented by Dr. Lu Tong, possesses profound insights into the healthcare industry and access to top-tier medical resources. The company’s forward-looking and unique strategic vision is also highly impressive. We are confident that, under the leadership of its founding team and with the support of both new and existing shareholders, Visual MedTech will stand out in the era of digital surgery and become a major force in the fields of digital surgery and medical robotics in China and globally.

Mr. Ji Guoming, Partner at Langma Peak VenturesStatement: Langmafeng Venture Capital pays close attention to the penetration of digital technologies in the medical field, and we believe that remarkable platform-type companies will continue to emerge from this trend. Visual MedTech has built a closed-loop product matrix covering the entire surgical workflow, ranging from infrastructure for interoperable imaging information, to intelligent surgical planning, intraoperative mixed-reality high-dimensional navigation and precise robotic execution, as well as diverse smart consumables. This brings significant benefits to physicians, patients, and the entire surgical ecosystem. Notably, while possessing top-tier innovation capabilities in medical-engineering integration, the company also demonstrates leading revenue-generating capacity within its sector. Visual MedTech’s twenty years of dedicated accumulation in digital surgery and medical robotics have shown us that the era of digital surgery is approaching, with limitless prospects ahead.

JiangLu Zhihua, Deputy Director of the Jiangsu Industrial Technology Research InstituteIt is evident that “digitalization” is permeating every aspect of healthcare, ranging from precision clinical pathways to customized medical products, and from big data analytics in healthcare to digital medical science. Traditional experience-based medicine is transitioning toward digital medicine, characterized by informatization. As a key new-type R&D institution jointly established by Jiangsu Province and Changzhou City, the Jiangsu-Israel Institute of Industrial Technology Research is actively promoting the innovative transformation of local medical device enterprises in Changzhou, Jiangsu, and making significant strides in laying out the digital healthcare industry. In 2021, the Jiangsu-Israel Institute partnered with the National Clinical Research Center for Orthopedics and Sports Rehabilitation and Visual MedTech Co., Ltd. to establish the Industrial Innovation Center of the National Clinical Research Center for Orthopedics and Sports Rehabilitation, dedicated to redefining the new ecosystem for the development of the industrial chain in orthopedics and even the entire field of clinical medicine.

Existing shareholder, Mr. Wang Junfeng, Managing Director of Legend CapitalLegend Capital pays close attention to the critical sector of surgical robotics, which represents an inevitable trend in the development of digital surgery. Chinese surgical robotics companies have the opportunity to achieve convergence in hardware, drive innovation in software, and surpass competitors in intelligence. The team at Visual MedTech is a pioneer and explorer in surgical intelligence and digitalization, as well as a rigorous practitioner. The company also benefits from abundant clinical resources, aligning with Legend Capital’s longstanding principle of “business first, people foremost.” We are pleased to see Visual MedTech gain recognition from more investment partners, and we remain committed to continuously supporting the team and growing alongside the company.

Dr. Zou Guowen, Founding Partner of WinX CapitalWinX Capital is honored to have assisted Visual MedTech in completing this round of financing. As a pioneer in digital and intelligent surgery in China, Visual MedTech boasts a founding team with complementary strengths, possessing the most profound technological expertise, deepest medical insights, and richest market experience in the fields of surgical robotics and digital surgery. Leveraging its core technologies and robust clinical resources, the company is exceptionally rare in China for achieving a combinatorial layout across multiple departments and product lines, thereby realizing synergy and integration. With its forward-looking strategic planning and clear, smooth commercial pathway, we believe that, empowered by additional strong shareholders, Visual MedTech will further accelerate its pace in pioneering a new era of digital surgery.